{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:24:45Z","timestamp":1791177885716,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":192,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_828","type":"book-chapter","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:58:43Z","timestamp":1784224723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-2063","authenticated-orcid":false,"given":"Volker","family":"Vallon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"828_CR1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559","journal-title":"N Engl J Med"},{"key":"828_CR2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","volume":"15","author":"G Bakris","year":"2020","unstructured":"Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V (2020) Effects of Canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE Trial. Clin J Am Soc Nephrol 15:1705\u20131714","journal-title":"Clin J Am Soc Nephrol"},{"key":"828_CR3","doi-asserted-by":"crossref","first-page":"C475","DOI":"10.1152\/ajpcell.00180.2008","volume":"295","author":"D Balen","year":"2008","unstructured":"Balen D, Ljubojevic M, Breljak D, Brzica H, Zlender V, Koepsell H, Sabolic I (2008) Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol 295:C475\u2013C489","journal-title":"Am J Physiol Cell Physiol"},{"key":"828_CR4","first-page":"F322","volume":"241","author":"DW Barfuss","year":"1981","unstructured":"Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Phys 241:F322\u2013F332","journal-title":"Am J Phys"},{"key":"828_CR5","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1210\/clinem\/dgad088","volume":"108","author":"E Biancalana","year":"2023","unstructured":"Biancalana E, Rossi C, Raggi F, Distaso M, Trico D, Baldi S, Ferrannini E, Solini A (2023) Empagliflozin and renal sodium-hydrogen exchange in healthy subjects. J Clin Endocrinol Metab 108:e567\u2013e573","journal-title":"J Clin Endocrinol Metab"},{"key":"828_CR6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","volume":"149","author":"AM Billing","year":"2024","unstructured":"Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, Demir F, Kovalenko E, Lasse M, Dugourd A, Fallegger R, Klampe B, Jaegers J, Li Q, Kravtsova O, Crespo-Masip M, Palermo A, Fenton RA, Hoxha E, Blankenberg S, Kirchhof P, Huber TB, Laugesen E, Zeller T, Chrysopoulou M, Saez-Rodriguez J, Magnussen C, Eschenhagen T, Staruschenko A, Siuzdak G, Poulsen PL, Schwab C, Cuello F, Vallon V, Rinschen MM (2024) Metabolic communication by SGLT2 inhibition. Circulation 149:860\u2013884","journal-title":"Circulation"},{"key":"828_CR7","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1681\/ASN.2020071029","volume":"32","author":"FA Borges-Junior","year":"2021","unstructured":"Borges-Junior FA, Silva Dos Santos D, Benetti A, Polidoro JZ, Wisnivesky ACT, Crajoinas RO, Antonio EL, Jensen L, Caramelli B, Malnic G, Tucci PJ, Girardi ACC (2021) Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR, and restores Euvolemia in nondiabetic rats with induced heart failure. J Am Soc Nephrol 32:1616\u20131629","journal-title":"J Am Soc Nephrol"},{"key":"828_CR8","doi-asserted-by":"publisher","unstructured":"Bou Antoun MT, Borghol AH, Souvalian L, Hadla M, Abboud G, Ghanem A, Munairdjy Debeh FG, Mardirossian JM, Salih M, Garimella PS, Vallon V, Chebib FT (2025) Sodium-glucose cotransporter 2 inhibitors in autosomal dominant polycystic Kidney disease: mechanistic insights and therapeutic promise. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000943","DOI":"10.1681\/ASN.0000000943"},{"key":"828_CR9","first-page":"F246","volume":"235","author":"HB Burch","year":"1978","unstructured":"Burch HB, Narins RG, Chu C, Fagioli S, Choi S, McCarthy W, Lowry OH (1978) Distribution along the rat nephron of three enzymes of gluconeogenesis in acidosis and starvation. Am J Phys 235:F246\u2013F253","journal-title":"Am J Phys"},{"key":"828_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10254-002-0003-8","volume":"146","author":"BC Burckhardt","year":"2003","unstructured":"Burckhardt BC, Burckhardt G (2003) Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 146:95\u2013158","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"828_CR11","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI116392","volume":"91","author":"E Chin","year":"1993","unstructured":"Chin E, Zhou J, Bondy C (1993) Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest 91:1810\u20131815","journal-title":"J Clin Invest"},{"key":"828_CR12","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","volume":"117","author":"YJ Chung","year":"2021","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ (2021) Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res 117:2794\u20132806","journal-title":"Cardiovasc Res"},{"key":"828_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","volume":"28","author":"MJ Coady","year":"2017","unstructured":"Coady MJ, El Tarazi A, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY (2017) MAP 17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85\u201393","journal-title":"J Am Soc Nephrol"},{"key":"828_CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11892-022-01461-4","volume":"22","author":"S Cohen","year":"2022","unstructured":"Cohen S, Sternlicht H, Bakris GL (2022) Mineralocorticoid receptor antagonists in the treatment of diabetic Kidney disease: their application in the era of SGLT2 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 22:213\u2013218","journal-title":"Curr Diab Rep"},{"key":"828_CR15","doi-asserted-by":"crossref","first-page":"F662","DOI":"10.1152\/ajprenal.00031.2025","volume":"328","author":"M Crespo-Masip","year":"2025","unstructured":"Crespo-Masip M, Goodluck HA, Kim YC, Oe Y, Roach AM, Kanoo S, Lopez N, Zhang H, Badal SS, Vallon V (2025) ASK1 limits kidney glucose reabsorption, growth, and mid-late proximal tubule KIM-1 induction when diabetes and Western diet are combined with SGLT2 inhibition. Am J Physiol Renal Physiol 328:F662\u2013F675","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR16","doi-asserted-by":"crossref","first-page":"e168825","DOI":"10.1172\/jci.insight.168825","volume":"9","author":"M Darshi","year":"2024","unstructured":"Darshi M, Kugathasan L, Maity S, Sridhar VS, Fernandez R, Limonte CP, Grajeda BI, Saliba A, Zhang G, Drel VR, Kim JJ, Montellano R, Tumova J, Montemayor D, Wang Z, Liu JJ, Wang J, Perkins BA, Lytvyn Y, Natarajan L, Lim SC, Feldman H, Toto R, Sedor JR, Patel J, Waikar SS, Brown J, Osman Y, He J, Chen J, Reeves WB, de Boer IH, Roy S, Vallon V, Hallan S, Gelfond JA, Cherney DZ, Sharma K, Kidney Precision Medicine P, the CSI (2024) Glycolytic lactate in diabetic kidney disease. JCI Insight 9:e168825","journal-title":"JCI Insight"},{"key":"828_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2215\/CJN.04530418","volume":"14","author":"MA de Jong","year":"2019","unstructured":"de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH (2019) Effects of Dapagliflozin on circulating markers of phosphate homeostasis. Clin J Am Soc Nephrol 14:66\u201373","journal-title":"Clin J Am Soc Nephrol"},{"key":"828_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA Defronzo","year":"2009","unstructured":"Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773\u2013795","journal-title":"Diabetes"},{"key":"828_CR19","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20:1988\u20131993","journal-title":"Diabetes Obes Metab"},{"key":"828_CR20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977\u2013986","journal-title":"N Engl J Med"},{"key":"828_CR21","first-page":"F807","volume":"262","author":"JH Dominguez","year":"1992","unstructured":"Dominguez JH, Camp K, Maianu L, Garvey WT (1992) Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Phys 262:F807\u2013F812","journal-title":"Am J Phys"},{"key":"828_CR22","first-page":"3","volume":"53","author":"KD Drewnowsk","year":"2002","unstructured":"Drewnowsk KD, Craig MR, Digiovanni SR, McCarty JM, Moorman AF, Lamers WH, Schoolwerth AC (2002) PEPCK mRNA localization in proximal tubule and gene regulation during metabolic acidosis. J Physiol Pharmacol 53:3\u201320","journal-title":"J Physiol Pharmacol"},{"key":"828_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, Zuurbier CJ (2022) Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol 167:17\u201331","journal-title":"J Mol Cell Cardiol"},{"key":"828_CR24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.1160406","volume":"321","author":"S Faham","year":"2008","unstructured":"Faham S, Watanabe A, Besserer GM, Cascio D, Specht A, Hirayama BA, Wright EM, Abramson J (2008) The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+\/sugar symport. Science 321:810\u2013814","journal-title":"Science"},{"issue":"7","key":"828_CR25","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.0000000000000357","volume":"35","author":"A Faivre","year":"2024","unstructured":"Faivre A, Bugarski M, Rinaldi A, Sakhi IB, Verissimo T, Legouis D, Correia S, Kaminska M, Dalga D, Malpetti D, Cippa PE, de Seigneux S, Hall AM (2024) Spatiotemporal landscape of kidney tubular responses to glomerular proteinuria. J Am Soc Nephrol 35(7):854\u2013869","journal-title":"J Am Soc Nephrol"},{"key":"828_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","volume":"30","author":"SJ Farber","year":"1951","unstructured":"Farber SJ, Berger EY, Earle DP (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125\u2013129","journal-title":"J Clin Invest"},{"key":"828_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-018-0901-y","volume":"78","author":"H Fattah","year":"2018","unstructured":"Fattah H, Vallon V (2018) The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs 78:717\u2013726","journal-title":"Drugs"},{"key":"828_CR28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"828_CR29","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E (2015) Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1730\u20131735","journal-title":"Diabetes Care"},{"key":"828_CR30","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39:1108\u20131114","journal-title":"Diabetes Care"},{"key":"828_CR31","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","volume":"8","author":"D Fitchett","year":"2021","unstructured":"Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F (2021) Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail 8:4517\u20134527","journal-title":"ESC Heart Fail"},{"key":"828_CR32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","volume":"149","author":"HS Freitas","year":"2008","unstructured":"Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF (2008) Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149:717\u2013724","journal-title":"Endocrinology"},{"key":"828_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mce.2009.02.014","volume":"305","author":"HS Freitas","year":"2009","unstructured":"Freitas HS, Schaan BD, David-Silva A, Sabino-Silva R, Okamoto MM, Alves-Wagner AB, Mori RC, Machado UF (2009) SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol Cell Endocrinol 305:63\u201370","journal-title":"Mol Cell Endocrinol"},{"key":"828_CR34","volume-title":"SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration diabetes","author":"Y Fu","year":"2014","unstructured":"Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V (2014) SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration diabetes. American Diabetes Association, Alexandria"},{"key":"828_CR35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","volume":"23","author":"S Fujiki","year":"2024","unstructured":"Fujiki S, Iijima K, Nakagawa Y, Takahashi K, Okabe M, Kusano K, Owada S, Kondo Y, Tsujita K, Shimizu W, Tomita H, Watanabe M, Shoda M, Watanabe M, Tokano T, Murohara T, Kaneshiro T, Kato T, Hayashi H, Maemura K, Niwano S, Umemoto T, Yoshida H, Ota K, Tanaka T, Kitamura N, Node K, Minamino T, Investigators EI (2024) Effect of Empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable Cardioverter-defibrillator: the EMPA-ICD trial. Cardiovasc Diabetol 23:224","journal-title":"Cardiovasc Diabetol"},{"key":"828_CR36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78\u201389","journal-title":"Diab Vasc Dis Res"},{"key":"828_CR37","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","volume":"307","author":"F Gembardt","year":"2014","unstructured":"Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307:F317\u2013F325","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136\u2013142","journal-title":"Diabet Med"},{"key":"828_CR39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","volume":"24","author":"JE Gerich","year":"2001","unstructured":"Gerich JE, Meyer C, Woerle HJ, Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382\u2013391","journal-title":"Diabetes Care"},{"key":"828_CR40","doi-asserted-by":"crossref","first-page":"C348","DOI":"10.1152\/ajpcell.00115.2012","volume":"303","author":"C Ghezzi","year":"2012","unstructured":"Ghezzi C, Wright EM (2012) Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 303:C348\u2013C354","journal-title":"Am J Physiol Cell Physiol"},{"key":"828_CR41","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","volume":"21","author":"RE Gilbert","year":"2019","unstructured":"Gilbert RE, Thorpe KE (2019) Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21:1996\u20132000","journal-title":"Diabetes Obes Metab"},{"key":"828_CR42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1681\/ASN.0000000515","volume":"36","author":"C Ginsberg","year":"2025","unstructured":"Ginsberg C, Seegmiller JC, Vallon V, SeungMi Jin S, Thomas RL, Boeder SC, Pettus J, Ix JH (2025) Acetazolamide therapy and Kidney function in persons with Nonalbuminuric diabetes mellitus type 1. J Am Soc Nephrol 36:463\u2013470","journal-title":"J Am Soc Nephrol"},{"key":"828_CR43","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.70217","volume":"13","author":"H Goodluck","year":"2025","unstructured":"Goodluck H, Zemljic-Harpf A, Galdino OA, Kanoo S, Lopez N, Kim YC, Vallon V (2025) Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice. Physiol Rep 13:e70217","journal-title":"Physiol Rep"},{"key":"828_CR44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187\u2013196","journal-title":"Diabetes"},{"key":"828_CR45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.1984.143","volume":"26","author":"WG Guder","year":"1984","unstructured":"Guder WG, Ross BD (1984) Enzyme distribution along the nephron. Kidney Int 26:101\u2013111","journal-title":"Kidney Int"},{"key":"828_CR46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","volume":"66","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, Vernstrom L, Sorensen SS, Ringgaard S, Laustsen C, Funck KL, Poulsen PL, Laugesen E (2023) Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia 66:813\u2013825","journal-title":"Diabetologia"},{"key":"828_CR47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174558","volume":"134","author":"G Gyarmati","year":"2024","unstructured":"Gyarmati G, Shroff UN, Riquier-Brison A, Desposito D, Ju W, Stocker SD, Izuhara A, Deepak S, Becerra Calderon A, Burford JL, Kadoya H, Moon JY, Chen Y, Rinschen MM, Ahmadi N, Lau L, Biemesderfer D, James AW, Minichiello L, Zlokovic BV, Gill IS, Kretzler M, Peti-Peterdi J (2024) Neuronally differentiated macula densa cells regulate tissue remodeling and regeneration in the kidney. J Clin Invest 134:e174558","journal-title":"J Clin Invest"},{"key":"828_CR48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479\u2013487","journal-title":"Diabetes Obes Metab"},{"key":"828_CR49","doi-asserted-by":"crossref","first-page":"F988","DOI":"10.1152\/ajprenal.00327.2004","volume":"288","author":"HJ Han","year":"2005","unstructured":"Han HJ, Lee YJ, Park SH, Lee JH, Taub M (2005) High glucose-induced oxidative stress inhibits Na+\/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol 288:F988\u2013F996","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","volume":"330","author":"MA Hediger","year":"1987","unstructured":"Hediger MA, Coady MJ, Ikeda TS, Wright EM (1987) Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter. Nature 330:379\u2013381","journal-title":"Nature"},{"key":"828_CR51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, Committees D-CT, Investigators (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:743\u2013754","journal-title":"Lancet Diabetes Endocrinol"},{"key":"828_CR52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613\u2013621","journal-title":"Diabetes Obes Metab"},{"key":"828_CR53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282\u2013287","journal-title":"Kidney Int"},{"key":"828_CR54","doi-asserted-by":"publisher","unstructured":"Hsu CK, Chang LC, Chen YT, Chen CY, Hsu HR, Bai S, Lee CC, Jangir H, Sun CY, Su SC, Wu IW (2025) Effects of SGLT2 inhibitors on modulating protein-bound uremic toxins and gut microbiota in pre-dialysis CKD patients: a matched case-control study. Kidney360. https:\/\/doi.org\/10.34067\/KID.0000000792","DOI":"10.34067\/KID.0000000792"},{"key":"828_CR55","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"CS Hummel","year":"2011","unstructured":"Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14\u2013C21","journal-title":"Am J Physiol Cell Physiol"},{"key":"828_CR56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM (2018) How does Empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356\u2013363","journal-title":"Diabetes Care"},{"key":"828_CR57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molmet.2015.02.003","volume":"4","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Rose AJ, Sijmonsma TP, Broer A, Pfenninger A, Herzig S, Schmoll D, Broer S (2015) Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control. Mol Metab 4:406\u2013417","journal-title":"Mol Metab"},{"key":"828_CR58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397\u2013404","journal-title":"J Clin Invest"},{"key":"828_CR59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365","volume":"14","author":"K Katsurada","year":"2021","unstructured":"Katsurada K, Nandi SS, Sharma NM, Patel KP (2021) Enhanced expression and function of renal SGLT2 (Sodium-Glucose Cotransporter 2) in heart failure: role of renal nerves. Circ Heart Fail 14:e008365","journal-title":"Circ Heart Fail"},{"key":"828_CR60","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38:316\u2013322","journal-title":"Diabetes Care"},{"key":"828_CR61","doi-asserted-by":"crossref","first-page":"F68","DOI":"10.1152\/ajprenal.00231.2024","volume":"328","author":"YC Kim","year":"2025","unstructured":"Kim YC, Das V, Kanoo S, Yao H, Stanford SM, Bottini N, Karihaloo A, Vallon V (2025) Transcriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1\/2 inhibition, or GLP1 receptor agonism. Am J Physiol Renal Physiol 328:F68\u2013F81","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR2000","doi-asserted-by":"publisher","unstructured":"Kim YC, Meng C, Kanoo S, Thomson S, Karihaloo A, Vallon V (2026) Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1\/2 inhibition, or GLP1 receptor agonism. Am J Physiol Renal Physiol 331(1):F39\u2013F55. https:\/\/doi.org\/10.1152\/ajprenal.00109.2026","DOI":"10.1152\/ajprenal.00109.2026"},{"key":"828_CR62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.1981.100","volume":"20","author":"KL Klein","year":"1981","unstructured":"Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K (1981) Substrate oxidation by isolated single nephron segments of the rat. Kidney Int 20:29\u201335","journal-title":"Kidney Int"},{"key":"828_CR63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520\u2013526","journal-title":"Clin Pharmacol Ther"},{"key":"828_CR64","doi-asserted-by":"crossref","first-page":"E859","DOI":"10.1152\/ajpendo.00165.2014","volume":"307","author":"GM Kowalski","year":"2014","unstructured":"Kowalski GM, Bruce CR (2014) The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab 307:E859\u2013E871","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"828_CR65","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"key":"828_CR66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100895","volume":"37","author":"JC Laursen","year":"2021","unstructured":"Laursen JC, Sondergaard-Heinrich N, de Melo JML, Haddock B, Rasmussen IKB, Safavimanesh F, Hansen CS, Storling J, Larsson HBW, Groop PH, Frimodt-Moller M, Andersen UB, Rossing P (2021) Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine 37:100895","journal-title":"EClinicalMedicine"},{"key":"828_CR67","doi-asserted-by":"crossref","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","volume":"314","author":"AT Layton","year":"2018","unstructured":"Layton AT, Vallon V (2018) SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol 314:F969\u2013F984","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR68","doi-asserted-by":"crossref","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","volume":"308","author":"AT Layton","year":"2015","unstructured":"Layton AT, Vallon V, Edwards A (2015) Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol 308:F1343\u2013F1357","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR69","doi-asserted-by":"crossref","first-page":"F1217","DOI":"10.1152\/ajprenal.00294.2016","volume":"311","author":"AT Layton","year":"2016","unstructured":"Layton AT, Laghmani K, Vallon V, Edwards A (2016) Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors. Am J Physiol Renal Physiol 311:F1217\u2013F1229","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR70","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","volume":"269","author":"WS Lee","year":"1994","unstructured":"Lee WS, Kanai Y, Wells RG, Hediger MA (1994) The high affinity Na+\/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269:12032\u201312039","journal-title":"J Biol Chem"},{"key":"828_CR71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li J, Neal B, Perkovic V, de Zeeuw D, Neuen BL, Arnott C, Simpson R, Oh R, Mahaffey KW, Heerspink HJL (2020a) Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int 98:769\u2013777","journal-title":"Kidney Int"},{"key":"828_CR72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B (2020b) Mediators of the effects of Canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Failure 8:57\u201366","journal-title":"JACC Heart Failure"},{"key":"828_CR73","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","volume":"23","author":"J Liao","year":"2024","unstructured":"Liao J, Ebrahimi R, Ling Z, Meyer C, Martinek M, Sommer P, Futyma P, Di Vece D, Schratter A, Acou WJ, Zhu L, Kiuchi MG, Liu S, Yin Y, Purerfellner H, Templin C, Chen S (2024) Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-arrhythmias and sudden cardiac death). Cardiovasc Diabetol 23:78","journal-title":"Cardiovasc Diabetol"},{"key":"828_CR74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11892-022-01471-2","volume":"22","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI (2022) SGLT2 inhibition in type 1 diabetes with diabetic Kidney disease: potential Cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis. Curr Diab Rep 22:317\u2013332","journal-title":"Curr Diab Rep"},{"key":"828_CR75","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","volume":"146","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, Perkins BA, Soleymanlou N, Cherney DZI (2022) Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition. Circulation 146:450\u2013462","journal-title":"Circulation"},{"key":"828_CR76","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00424-017-2056-1","volume":"469","author":"IV Madunic","year":"2017","unstructured":"Madunic IV, Breljak D, Karaica D, Koepsell H, Sabolic I (2017) Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pflugers Arch 469:1545\u20131565","journal-title":"Pflugers Arch"},{"key":"828_CR77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1523-1755.2005.00053.x","volume":"67","author":"D Magen","year":"2005","unstructured":"Magen D, Sprecher E, Zelikovic I, Skorecki K (2005) A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67:34\u201341","journal-title":"Kidney Int"},{"key":"828_CR78","doi-asserted-by":"publisher","unstructured":"Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Gorriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03133-0","DOI":"10.1038\/s41591-024-03133-0"},{"key":"828_CR79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ng0296-216","volume":"12","author":"MG Martin","year":"1996","unstructured":"Martin MG, Turk E, Lostao MP, Kerner C, Wright EM (1996) Defects in Na+\/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12:216\u2013220","journal-title":"Nat Genet"},{"key":"828_CR80","doi-asserted-by":"crossref","first-page":"e173675","DOI":"10.1172\/jci.insight.173675","volume":"9","author":"MA Martinez-Rojas","year":"2024","unstructured":"Martinez-Rojas MA, Balcazar H, Gonzalez-Soria I, Gonzalez-Rivera JM, Rodriguez-Vergara ME, Velazquez-Villegas LA, Leon-Contreras JC, Perez-Villalva R, Correa F, Rosetti F, Bobadilla NA (2024) Transient inhibition of sodium-glucose cotransporter 2 after ischemia\/reperfusion injury ameliorates chronic kidney disease. JCI Insight 9:e173675","journal-title":"JCI Insight"},{"key":"828_CR81","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D (2020) Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep 8:e14360","journal-title":"Physiol Rep"},{"key":"828_CR82","doi-asserted-by":"crossref","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","volume":"323","author":"T Masuda","year":"2022","unstructured":"Masuda T, Ohara K, Vallon V, Nagata D (2022) SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Renal Physiol 323:F361\u2013F369","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","volume":"35","author":"KJ Mayne","year":"2024","unstructured":"Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZ, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Bruckmann M, Landray MJ, Baigent FC, Haynes R, Herrington WG, centers E-KCGSSMfflotc, site staff from the E-KCGwcttS (2024) Effects of Empagliflozin on fluid overload, weight and blood pressure in chronic Kidney disease. J Am Soc Nephrol 35:202\u2013215","journal-title":"J Am Soc Nephrol"},{"key":"828_CR84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","volume":"28","author":"CE Mogensen","year":"1971","unstructured":"Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101\u2013109","journal-title":"Scand J Clin Lab Invest"},{"key":"828_CR85","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc22-2003","volume":"46","author":"D Moriconi","year":"2023","unstructured":"Moriconi D, Sacchetta L, Chiriaco M, Nesti L, Forotti G, Natali A, Solini A, Trico D (2023) Glomerular Hyperfiltration predicts Kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study. Diabetes Care 46:845\u2013853","journal-title":"Diabetes Care"},{"key":"828_CR86","doi-asserted-by":"publisher","unstructured":"Mozaffari SV, De Jong HN, Scherer N, Butz E, Ullman J, Sallee NA, Hoek M, Graham RR, Kottgen A, Estrada K (2025) Experimentally validated SLC6A19 loss-of-function variants improve Kidney function and reduce progression to Kidney failure. J Am Soc Nephrol 36. https:\/\/doi.org\/10.1681\/ASN.20253ga66hkv","DOI":"10.1681\/ASN.20253ga66hkv"},{"key":"828_CR87","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial Cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39:1115\u20131122","journal-title":"Diabetes Care"},{"issue":"11","key":"828_CR88","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/dom.13823","volume":"21","author":"S Mulder","year":"2019","unstructured":"Mulder S, Heerspink HJL, Darshi M, Kim JJ, Laverman GD, Sharma K, Pena MJ (2019) Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes Obes Metab 21(11):2422\u20132428","journal-title":"Diabetes Obes Metab"},{"key":"828_CR89","doi-asserted-by":"crossref","first-page":"335","DOI":"10.34067\/KID.0000000000000375","volume":"5","author":"DP Murphy","year":"2024","unstructured":"Murphy DP, Wolfson J, Reule S, Johansen KL, Ishani A, Drawz PE (2024) Kidney outcomes with sodium-glucose Cotransporter-2 inhibitor initiation after AKI among veterans with diabetic Kidney disease. Kidney360 5:335\u2013343","journal-title":"Kidney360"},{"key":"828_CR90","doi-asserted-by":"crossref","first-page":"F455","DOI":"10.1152\/ajprenal.00181.2022","volume":"323","author":"A Navarro Garrido","year":"2022","unstructured":"Navarro Garrido A, Kim YC, Oe Y, Zhang H, Crespo-Masip M, Goodluck HA, Kanoo S, Sanders PW, Broer S, Vallon V (2022) Aristolochic acid-induced nephropathy is attenuated in mice lacking the neutral amino acid transporter B(0)AT1 (Slc6a19). Am J Physiol Renal Physiol 323:F455\u2013F467","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR91","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"key":"828_CR92","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL (2022) Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145:1460\u20131470","journal-title":"Circulation"},{"key":"828_CR93","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","volume":"601","author":"Y Niu","year":"2022","unstructured":"Niu Y, Liu R, Guan C, Zhang Y, Chen Z, Hoerer S, Nar H, Chen L (2022) Structural basis of inhibition of the human SGLT2-MAP 17 glucose transporter. Nature 601:280\u2013284","journal-title":"Nature"},{"key":"828_CR94","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/dom.13003","volume":"19","author":"L Norton","year":"2017","unstructured":"Norton L, Shannon CE, Fourcaudot M, Hu C, Wang N, Ren W, Song J, Abdul-Ghani M, DeFronzo RA, Ren J, Jia W (2017) Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 19:1322\u20131326","journal-title":"Diabetes Obes Metab"},{"key":"828_CR95","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C, Koepsell H, Busslinger M, Onishi A, Nespoux J, Vallon V (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol 316:F173\u2013F185","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR96","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801","journal-title":"Lancet"},{"key":"828_CR97","first-page":"93","volume":"17","author":"GT O\u2019Bryan","year":"1997","unstructured":"O\u2019Bryan GT, Hostetter TH (1997) The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol 17:93\u2013100","journal-title":"Semin Nephrol"},{"key":"828_CR98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/kidneydial2020032","volume":"2","author":"Y Oe","year":"2022","unstructured":"Oe Y, Vallon V (2022) The pathophysiological basis of diabetic Kidney protection by inhibition of SGLT2 and SGLT1. Kidney Dial 2:349\u2013368","journal-title":"Kidney Dial"},{"key":"828_CR99","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00228.2023","volume":"326","author":"Y Oe","year":"2024","unstructured":"Oe Y, Kim YC, Sidorenko VS, Zhang H, Kanoo S, Lopez N, Goodluck HA, Crespo-Masip M, Vallon V (2024) SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy. Am J Physiol Renal Physiol 326:F227\u2013F240","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR100","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V (2020) A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol 319:F712\u2013F728","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR101","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.diabres.2009.09.006","volume":"86","author":"H Osorio","year":"2009","unstructured":"Osorio H, Bautista R, Rios A, Franco M, Santamaria J, Escalante B (2009) Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 86:e46\u2013e49","journal-title":"Diabetes Res Clin Pract"},{"issue":"928\u2013942","key":"828_CR102","volume":"35","author":"M Ozcan","year":"2023","unstructured":"Ozcan M, Guo Z, Valenzuela Ripoll C, Diab A, Picataggi A, Rawnsley D, Lotfinaghsh A, Bergom C, Szymanski J, Hwang D, Asnani A, Kosiborod M, Zheng J, Hayashi RJ, Woodard PK, Kovacs A, Margulies KB, Schilling J, Razani B, Diwan A, Javaheri A (2023) Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity. Cell Metab 35(928\u2013942):e4","journal-title":"Cell Metab"},{"key":"828_CR103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","volume":"119","author":"A Paasche","year":"2024","unstructured":"Paasche A, Wiedmann F, Kraft M, Seibertz F, Herlt V, Blochberger PL, Javorszky N, Beck M, Weirauch L, Seeger T, Blank A, Haefeli WE, Arif R, Meyer AL, Warnecke G, Karck M, Voigt N, Frey N, Schmidt C (2024) Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol 119:93\u2013112","journal-title":"Basic Res Cardiol"},{"key":"828_CR104","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M (2020) SGLT2 inhibitors produce Cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508\u2013511","journal-title":"Diabetes Care"},{"key":"828_CR105","volume":"7","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Huang TT, Sun CY, Wang SI, Wei JC, Wu VC (2024) Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute Kidney disease. JAMA Netw Open 7:e2350050","journal-title":"JAMA Netw Open"},{"key":"828_CR106","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1038\/s41467-025-65402-x","volume":"16","author":"X Pan","year":"2025","unstructured":"Pan X, Mowdawalla C, Bagnato S, Pessin J, Vallon V, Hussain MM (2025) Fasting hijacks proximal tubule circadian control mechanisms to regulate glucose reabsorption via the Nrf1\/Sglt2 pathway in mice. Nat Commun 16:10447","journal-title":"Nat Commun"},{"key":"828_CR107","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1530\/eje.0.1500627","volume":"150","author":"JM Pascual","year":"2004","unstructured":"Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC (2004) GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol 150:627\u2013633","journal-title":"Eur J Endocrinol"},{"key":"828_CR108","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","volume":"37","author":"BA Perkins","year":"2014","unstructured":"Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480\u20131483","journal-title":"Diabetes Care"},{"key":"828_CR109","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","volume":"10","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Rabin-Court SJD, Cardone RL, Wang Y, Kibbey RG, Shulman GI (2019) Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun 10:548","journal-title":"Nat Commun"},{"key":"828_CR110","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","volume":"25","author":"TD Pessoa","year":"2014","unstructured":"Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028\u20132039","journal-title":"J Am Soc Nephrol"},{"key":"828_CR111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","volume":"144","author":"B Pitt","year":"2021","unstructured":"Pitt B, Bhatt DL (2021) Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes? Circulation 144:4\u20136","journal-title":"Circulation"},{"key":"828_CR112","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117\u2013E130","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"828_CR113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.114.214304","volume":"350","author":"DR Powell","year":"2014","unstructured":"Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM (2014) Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther 350:232\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"828_CR114","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","volume":"93","author":"M Pruijm","year":"2018","unstructured":"Pruijm M, Milani B, Pivin E, Podhajska A, Vogt B, Stuber M, Burnier M (2018) Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int 93:932\u2013940","journal-title":"Kidney Int"},{"key":"828_CR115","first-page":"5","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V (2017) Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 33:5","journal-title":"Diabetes Metab Res Rev"},{"key":"828_CR116","first-page":"F151","volume":"253","author":"GA Quamme","year":"1987","unstructured":"Quamme GA, Freeman HJ (1987) Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney. Am J Phys 253:F151\u2013F157","journal-title":"Am J Phys"},{"key":"828_CR117","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427\u20133434","journal-title":"Diabetes"},{"key":"828_CR118","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1096\/fj.201700610RR","volume":"32","author":"P Rajkumar","year":"2018","unstructured":"Rajkumar P, Cha B, Yin J, Arend LJ, Paunescu TG, Hirabayashi Y, Donowitz M, Pluznick JL (2018) Identifying the localization and exploring a functional role for Gprc5c in the kidney. FASEB J 32:2046\u20132059","journal-title":"FASEB J"},{"issue":"2","key":"828_CR119","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.0000000000000269","volume":"35","author":"VS Rao","year":"2024","unstructured":"Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field MP, Wiederin DR, Butler J, Collins SP, Turner JM, Wilson FP, Inzucchi SE, Wilcox CS, Ellison DH, Testani JM (2024) Empagliflozin in heart failure: regional nephron sodium handling effects. J Am Soc Nephrol 35(2):189\u2013201","journal-title":"J Am Soc Nephrol"},{"key":"828_CR120","volume":"16","author":"M Rau","year":"2022","unstructured":"Rau M, Thiele K, Hartmann NK, Mollmann J, Wied S, Hohl M, Marx N, Lehrke M (2022) Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes \u2013 data from a randomized, placebo-controlled study. Bone Rep 16:101175","journal-title":"Bone Rep"},{"key":"828_CR121","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188\u2013F193","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR122","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","volume":"302","author":"I Sabolic","year":"2012","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174\u2013C1188","journal-title":"Am J Physiol Cell Physiol"},{"key":"828_CR123","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1113\/JP271904","volume":"594","author":"M Sala-Rabanal","year":"2016","unstructured":"Sala-Rabanal M, Hirayama BA, Ghezzi C, Liu J, Huang SC, Kepe V, Koepsell H, Yu A, Powell DR, Thorens B, Wright EM, Barrio JR (2016) Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol 594:4425\u20134438","journal-title":"J Physiol"},{"key":"828_CR124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133\u2013141","journal-title":"Clin J Am Soc Nephrol"},{"key":"828_CR125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s004310050937","volume":"157","author":"R Santer","year":"1998","unstructured":"Santer R, Schneppenheim R, Suter D, Schaub J, Steinmann B (1998) Fanconi-Bickel syndrome\u2013the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr 157:783\u2013797","journal-title":"Eur J Pediatr"},{"key":"828_CR126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00439-001-0638-6","volume":"110","author":"R Santer","year":"2002","unstructured":"Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, Leonard JV, Moses S, Norgren S, Skovby F, Schneppenheim R, Steinmann B, Schaub J (2002) The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet 110:21\u201329","journal-title":"Hum Genet"},{"issue":"5","key":"828_CR127","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164486","volume":"133","author":"JA Schaub","year":"2023","unstructured":"Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, Fermin D, O\u2019Connor C, Subramanian L, Bitzer M, Harned R, Ladd P, Pyle L, Pennathur S, Inoki K, Hodgin JB, Brosius FC, Nelson RG, Kretzler M, Bjornstad P (2023) SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes. J Clin Invest 133(5):e164486","journal-title":"J Clin Invest"},{"key":"828_CR128","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1681\/ASN.2006050454","volume":"18","author":"C Schmidt","year":"2007","unstructured":"Schmidt C, Hocherl K, Schweda F, Kurtz A, Bucher M (2007) Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 18:1072\u20131083","journal-title":"J Am Soc Nephrol"},{"key":"828_CR129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng0298-188","volume":"18","author":"G Seidner","year":"1998","unstructured":"Seidner G, Alvarez MG, Yeh JI, O\u2019Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC (1998) GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188\u2013191","journal-title":"Nat Genet"},{"key":"828_CR130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669\u2013672","journal-title":"Diabetes Obes Metab"},{"key":"828_CR131","doi-asserted-by":"crossref","first-page":"1118358","DOI":"10.3389\/fphar.2023.1118358","volume":"14","author":"F Sinha","year":"2023","unstructured":"Sinha F, Federlein A, Biesold A, Schwarzfischer M, Krieger K, Schweda F, Tauber P (2023) Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. Front Pharmacol 14:1118358","journal-title":"Front Pharmacol"},{"key":"828_CR132","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","volume":"19","author":"A Solini","year":"2017","unstructured":"Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E (2017) Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19:1289\u20131294","journal-title":"Diabetes Obes Metab"},{"key":"828_CR133","doi-asserted-by":"crossref","first-page":"F207","DOI":"10.1152\/ajprenal.00120.2019","volume":"317","author":"P Song","year":"2019","unstructured":"Song P, Huang W, Onishi A, Patel R, Kim YC, van Ginkel C, Fu Y, Freeman B, Koepsell H, Thomson S, Liu R, Vallon V (2019) Knockout of Na(+)-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration. Am J Physiol Renal Physiol 317:F207\u2013F217","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR134","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","volume":"17","author":"D Suijk","year":"2022","unstructured":"Suijk D, van Baar M, van Bommel E, Iqbal Z, Krebber M, Vallon V, Touw D, Hoorn E, Nieuwdorp M, Kramer M, Joles J, Bjornstad P, van Raalte D (2022) SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and Normal Kidney function. Clin J Am Soc Nephrol 17:663\u2013671","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"828_CR135","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2019.10.027","volume":"124","author":"SC Thomson","year":"2019","unstructured":"Thomson SC, Vallon V (2019) Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol 124(Suppl 1):S28\u2013S35","journal-title":"Am J Cardiol"},{"key":"828_CR136","doi-asserted-by":"crossref","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","volume":"320","author":"SC Thomson","year":"2021","unstructured":"Thomson SC, Vallon V (2021) Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats. Am J Physiol Renal Physiol 320:F761\u2013FF77","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR137","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75\u2013R83","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"828_CR138","first-page":"C286","volume":"259","author":"B Thorens","year":"1990","unstructured":"Thorens B, Lodish HF, Brown D (1990) Differential localization of two glucose transporter isoforms in rat kidney. Am J Phys 259:C286\u2013C294","journal-title":"Am J Phys"},{"key":"828_CR139","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0002-9343(76)90365-X","volume":"61","author":"K Thurau","year":"1976","unstructured":"Thurau K, Boylan JW (1976) Acute renal success. The unexpected logic of oliguria in acute renal failure. Am J Med 61:308\u2013315","journal-title":"Am J Med"},{"key":"828_CR140","doi-asserted-by":"crossref","first-page":"F974","DOI":"10.1152\/ajprenal.00149.2007","volume":"293","author":"S Tiwari","year":"2007","unstructured":"Tiwari S, Riazi S, Ecelbarger CA (2007) Insulin\u2019s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 293:F974\u2013F984","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR141","doi-asserted-by":"crossref","first-page":"F826","DOI":"10.1152\/ajprenal.00012.2017","volume":"313","author":"D Toyoki","year":"2017","unstructured":"Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, Uchida S (2017) Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol 313:F826\u2013F834","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR142","first-page":"F406","volume":"242","author":"RJ Turner","year":"1982","unstructured":"Turner RJ, Moran A (1982) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Phys 242:F406\u2013F414","journal-title":"Am J Phys"},{"key":"828_CR143","first-page":"F977","volume":"255","author":"S Uchida","year":"1988","unstructured":"Uchida S, Endou H (1988) Substrate specificity to maintain cellular ATP along the mouse nephron. Am J Phys 255:F977\u2013F983","journal-title":"Am J Phys"},{"key":"828_CR144","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757\u2013767","journal-title":"Lancet"},{"key":"828_CR145","doi-asserted-by":"crossref","first-page":"C6","DOI":"10.1152\/ajpcell.00444.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V (2011a) Molecular determinants of renal glucose transport. Am J Physiol Cell Physiol 300:C6\u2013C8","journal-title":"Am J Physiol Cell Physiol"},{"key":"828_CR146","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V (2011b) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300:R1009\u2013R1022","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"828_CR147","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255\u2013270","journal-title":"Annu Rev Med"},{"key":"828_CR148","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000446448","volume":"134","author":"V Vallon","year":"2016","unstructured":"Vallon V (2016) Tubular transport in acute Kidney injury: relevance for diagnosis, prognosis and intervention. Nephron 134:160\u2013166","journal-title":"Nephron"},{"key":"828_CR149","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00424-020-02361-w","volume":"472","author":"V Vallon","year":"2020","unstructured":"Vallon V (2020) Glucose transporters in the kidney in health and disease. Pflugers Arch 472:1345\u20131370","journal-title":"Pflugers Arch"},{"key":"828_CR150","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","volume":"39","author":"V Vallon","year":"2024","unstructured":"Vallon V (2024a) How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system? Nephrol Dial Transplant 39:1565\u20131573","journal-title":"Nephrol Dial Transplant"},{"key":"828_CR151","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V (2024b) State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens 37:841\u2013852","journal-title":"Am J Hypertens"},{"key":"828_CR152","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","volume":"1","author":"V Vallon","year":"2011","unstructured":"Vallon V, Komers R (2011) Pathophysiology of the diabetic kidney. Compr Physiol 1:1175\u20131232","journal-title":"Compr Physiol"},{"key":"828_CR153","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/j.2040-4603.2022.tb00207.x","volume":"12","author":"V Vallon","year":"2021","unstructured":"Vallon V, Nakagawa T (2021) Renal tubular handling of glucose and fructose in health and disease. Compr Physiol 12:2995\u20133044","journal-title":"Compr Physiol"},{"key":"828_CR154","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","volume":"74","author":"V Vallon","year":"2012","unstructured":"Vallon V, Thomson SC (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74:351\u2013375","journal-title":"Annu Rev Physiol"},{"key":"828_CR155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215\u2013225","journal-title":"Diabetologia"},{"key":"828_CR156","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 16:317\u2013336","journal-title":"Nat Rev Nephrol"},{"key":"828_CR157","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S (2021) Effects of SGLT2 inhibitors on Kidney and cardiovascular function. Annu Rev Physiol 83:503\u2013528","journal-title":"Annu Rev Physiol"},{"key":"828_CR158","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","volume":"10","author":"V Vallon","year":"1999","unstructured":"Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569\u20132576","journal-title":"J Am Soc Nephrol"},{"key":"828_CR159","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1681\/ASN.V12102003","volume":"12","author":"V Vallon","year":"2001","unstructured":"Vallon V, Grahammer F, Richter K, Bleich M, Lang F, Barhanin J, Volkl H, Warth R (2001) Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol 12:2003\u20132011","journal-title":"J Am Soc Nephrol"},{"key":"828_CR160","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ASN.0000016441.41118.57","volume":"13","author":"V Vallon","year":"2002","unstructured":"Vallon V, Huang DY, Deng A, Richter K, Blantz RC, Thomson S (2002) Salt-sensitivity of proximal reabsorption alters macula Densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus. J Am Soc Nephrol 13:1865\u20131871","journal-title":"J Am Soc Nephrol"},{"key":"828_CR161","doi-asserted-by":"crossref","first-page":"17864","DOI":"10.1073\/pnas.0505860102","volume":"102","author":"V Vallon","year":"2005","unstructured":"Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, Gerlach U, Rong Q, Pfeifer K, Lang F (2005) KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci USA 102:17864\u201317869","journal-title":"Proc Natl Acad Sci USA"},{"key":"828_CR162","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","volume":"86","author":"V Vallon","year":"2006","unstructured":"Vallon V, Muhlbauer B, Osswald H (2006) Adenosine and kidney function. Physiol Rev 86:901\u2013940","journal-title":"Physiol Rev"},{"key":"828_CR163","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2008020180","volume":"19","author":"V Vallon","year":"2008","unstructured":"Vallon V, Eraly SA, Wikoff WR, Rieg T, Kaler G, Truong DM, Ahn SY, Mahapatra NR, Mahata SK, Gangoiti JA, Wu W, Barshop BA, Siuzdak G, Nigam SK (2008) Organic anion transporter 3 contributes to the regulation of blood pressure. J Am Soc Nephrol 19:1732\u20131740","journal-title":"J Am Soc Nephrol"},{"key":"828_CR164","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"828_CR165","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304:F156\u2013F167","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR166","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:F194\u2013F204","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR167","first-page":"218","volume-title":"Brenner & rector\u2019s the kidney","author":"V Vallon","year":"2020","unstructured":"Vallon V, Broer S, Nigam SK (2020) Renal handling of organic solutes. In: Yu AS, Chertow G, Luyckx V, Marsden PA, Skorecki K, Taal MW (eds) Brenner & rector\u2019s the kidney. Elsevier, Philadelphia, pp 218\u2013246"},{"key":"828_CR168","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, Bozovic A, Danser AHJ, Geurts F, Hoorn EJ, Touw DJ, Larsen EL, Poulsen HE, Kramer MHH, Nieuwdorp M, Joles JA, van Raalte DH (2020) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97:202\u2013212","journal-title":"Kidney Int"},{"key":"828_CR169","doi-asserted-by":"publisher","unstructured":"van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJL (2023) Glycemic control and effects of Canagliflozin in reducing albuminuria and eGFR: a post hoc analysis of the CREDENCE trial. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.0000000000000161","DOI":"10.2215\/CJN.0000000000000161"},{"key":"828_CR170","volume":"240","author":"LAK van der Pluijm","year":"2024","unstructured":"van der Pluijm LAK, Koudijs A, Stam W, Roelofs J, Danser AHJ, Rotmans JI, Gross KW, Pieper MP, van Zonneveld AJ, Bijkerk R (2024) SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease. Acta Physiol (Oxf) 240:e14108","journal-title":"Acta Physiol (Oxf)"},{"key":"828_CR171","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","volume":"21","author":"CC van Ruiten","year":"2022","unstructured":"van Ruiten CC, Smits MM, Kok MD, Serne EH, van Raalte DH, Kramer MHH, Nieuwdorp M, IJzerman RG (2022) Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol 21:63","journal-title":"Cardiovasc Diabetol"},{"key":"828_CR172","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1681\/ASN.2021050680","volume":"33","author":"T Verissimo","year":"2022","unstructured":"Verissimo T, Faivre A, Rinaldi A, Lindenmeyer M, Delitsikou V, Veyrat-Durebex C, Heckenmeyer C, Fernandez M, Berchtold L, Dalga D, Cohen C, Naesens M, Ricksten SE, Martin PY, Pugin J, Merlier F, Haupt K, Rutkowski JM, Moll S, Cippa PE, Legouis D, de Seigneux S (2022) Decreased renal gluconeogenesis is a Hallmark of chronic Kidney disease. J Am Soc Nephrol 33:810\u2013827","journal-title":"J Am Soc Nephrol"},{"key":"828_CR173","doi-asserted-by":"crossref","first-page":"F532","DOI":"10.1152\/ajprenal.00038.2023","volume":"324","author":"T Verissimo","year":"2023","unstructured":"Verissimo T, Dalga D, Arnoux G, Sakhi I, Faivre A, Auwerx H, Bourgeois S, Paolucci D, Gex Q, Rutkowski JM, Legouis D, Wagner CA, Hall AM, de Seigneux S (2023) PCK1 is a key regulator of metabolic and mitochondrial functions in renal tubular cells. Am J Physiol Renal Physiol 324:F532\u2013F543","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR174","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/HCO.0000000000000647","volume":"34","author":"S Verma","year":"2019","unstructured":"Verma S, Sharma A, Kanumilli N, Butler J (2019) Predictors of heart failure development in type 2 diabetes: a practical approach. Curr Opin Cardiol 34:578\u2013583","journal-title":"Curr Opin Cardiol"},{"key":"828_CR175","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, Jadrijevic S, Aleksic I, Walles T, Sauvant C, Sabolic I, Koepsell H (2015) Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881\u20131898","journal-title":"Pflugers Arch"},{"key":"828_CR176","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D\u2019Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M (2017) SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292:5335\u20135348","journal-title":"J Biol Chem"},{"key":"828_CR177","first-page":"F459","volume":"263","author":"RG Wells","year":"1992","unstructured":"Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Phys 263:F459\u2013F465","journal-title":"Am J Phys"},{"key":"828_CR178","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007046","volume":"7","author":"CS Wilcox","year":"2018","unstructured":"Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC (2018) Interaction between the sodium-glucose-linked transporter 2 inhibitor Dapagliflozin and the loop diuretic bumetanide in Normal human subjects. J Am Heart Assoc 7:e007046","journal-title":"J Am Heart Assoc"},{"key":"828_CR179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89:3\u20139","journal-title":"Br J Nutr"},{"key":"828_CR180","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280:F10\u2013F18","journal-title":"Am J Physiol Renal Physiol"},{"key":"828_CR181","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","volume":"447","author":"EM Wright","year":"2004","unstructured":"Wright EM, Turk E (2004) The sodium\/glucose cotransport family SLC5. Pflugers Arch 447:510\u2013518","journal-title":"Pflugers Arch"},{"key":"828_CR182","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733\u2013794","journal-title":"Physiol Rev"},{"issue":"4","key":"828_CR183","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ymthe.2021.10.013","volume":"30","author":"J Wu","year":"2021","unstructured":"Wu J, Sun Z, Yang S, Fu J, Fan Y, Wang N, Hu J, Ma L, Peng C, Wang Z, Lee K, He JC, Li Q (2021) Kidney single-cell transcriptome profile reveals distinct response of proximal tubule cells to SGLT2i and ARB treatment in diabetic mice. Mol Ther 30(4):1741\u20131753","journal-title":"Mol Ther"},{"key":"828_CR184","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","volume":"270","author":"G You","year":"1995","unstructured":"You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA (1995) Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270:29365\u201329371","journal-title":"J Biol Chem"},{"key":"828_CR185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000455907","volume":"7","author":"AS You","year":"2017","unstructured":"You AS, Kalantar-Zadeh K, Lerner L, Nakata T, Lopez N, Lou L, Veliz M, Soohoo M, Jing J, Zaldivar F, Gyuris J, Nguyen DV, Rhee CM (2017) Association of Growth Differentiation Factor 15 with mortality in a prospective hemodialysis cohort. Cardiorenal Med 7:158\u2013168","journal-title":"Cardiorenal Med"},{"key":"828_CR186","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1074\/jbc.M113.526814","volume":"289","author":"JR Zapata-Morales","year":"2014","unstructured":"Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YMF (2014) Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem 289:346\u2013357","journal-title":"J Biol Chem"},{"key":"828_CR187","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2018080844","volume":"30","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wei J, Jiang S, Xu L, Wang L, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R (2019) Macula densa SGLT1-NOS1-TGF pathway \u2013 a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol 30:578\u2013593","journal-title":"J Am Soc Nephrol"},{"key":"828_CR188","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.kint.2021.10.037","volume":"101","author":"J Zhang","year":"2022","unstructured":"Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R (2022a) Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration. Kidney Int 101:541\u2013550","journal-title":"Kidney Int"},{"key":"828_CR189","doi-asserted-by":"crossref","first-page":"477","DOI":"10.34067\/KID.0006672021","volume":"3","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huan Y, Leibensperger M, Seo B, Song Y (2022b) Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials. Kidney360 3:477\u2013487","journal-title":"Kidney360"},{"issue":"8","key":"828_CR190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164610","volume":"133","author":"W Zhou","year":"2023","unstructured":"Zhou W, Simic P, Zhou IY, Caravan P, Vela Parada X, Wen D, Washington OL, Shvedova M, Pierce KA, Clish CB, Mannstadt M, Kobayashi T, Wein MN, Juppner H, Rhee EP (2023) Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis. J Clin Invest 133(8):e164610","journal-title":"J Clin Invest"},{"key":"828_CR191","first-page":"E409","volume":"276","author":"K Zierler","year":"1999","unstructured":"Zierler K (1999) Whole body glucose metabolism. Am J Phys 276:E409\u2013E426","journal-title":"Am J Phys"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:59:07Z","timestamp":1784224747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":192,"URL":"https:\/\/doi.org\/10.1007\/164_2026_828","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"17 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}